Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris Labaki

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
Immunity|November 1, 2025
Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinomaKevin Bi, Soki Kashima, Sabrina Y Camp, et al.
Clinical Genitourinary Cancer|August 9, 2022
CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)Vishal Navani, J Connor Wells, Devon J Boyne, et al.
European Urology|March 26, 2023
Corrigendum to "Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma" [Eur Urol 2023]Matthew S Ernst, Vishal Navani, J Connor Wells, et al.
European Urology|January 27, 2023
Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell CarcinomaMatthew S Ernst, Vishal Navani, J Connor Wells, et al.
Clinical Genitourinary Cancer|October 14, 2025
CABOSEQ 3-Comparison of Cabozantinib versus Sunitinib Following First-Line Nivolumab- Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)Audreylie Lemelin, David Maj, Kosuke Takemura, et al.
The Oncologist|April 17, 2024
Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimensEddy Saad, Georges Gebrael, Karl Semaan, et al.
Cancer|February 1, 2024
Comparison of outcomes for Hispanic and non-Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma DatabaseKripa Guram, Jiaming Huang, Christian Mouchati, et al.
Cancer Cell|January 16, 2026
A context-augmented large language model for accurate precision oncology medicine recommendationsHyeji Jun, Yutaro Tanaka, Shreya Johri, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Single-cell epigenetic profiling reveals an interferon response-high program associated with <i>BAP1</i> deficiency in kidney cancerSabrina Y Camp, Meng Xiao He, Michael S Cuoco, et al.
European Urology Oncology|November 3, 2022
Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumChun Loo Gan, Jiaming Huang, Elizabeth Pan, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Immunity|November 1, 2025
Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinomaKevin Bi, Soki Kashima, Sabrina Y Camp, et al.
Clinical Genitourinary Cancer|August 9, 2022
CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)Vishal Navani, J Connor Wells, Devon J Boyne, et al.
European Urology|March 26, 2023
Corrigendum to "Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma" [Eur Urol 2023]Matthew S Ernst, Vishal Navani, J Connor Wells, et al.
European Urology|January 27, 2023
Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell CarcinomaMatthew S Ernst, Vishal Navani, J Connor Wells, et al.
Clinical Genitourinary Cancer|October 14, 2025
CABOSEQ 3-Comparison of Cabozantinib versus Sunitinib Following First-Line Nivolumab- Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)Audreylie Lemelin, David Maj, Kosuke Takemura, et al.
The Oncologist|April 17, 2024
Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimensEddy Saad, Georges Gebrael, Karl Semaan, et al.
Cancer|February 1, 2024
Comparison of outcomes for Hispanic and non-Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma DatabaseKripa Guram, Jiaming Huang, Christian Mouchati, et al.
Cancer Cell|January 16, 2026
A context-augmented large language model for accurate precision oncology medicine recommendationsHyeji Jun, Yutaro Tanaka, Shreya Johri, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Single-cell epigenetic profiling reveals an interferon response-high program associated with <i>BAP1</i> deficiency in kidney cancerSabrina Y Camp, Meng Xiao He, Michael S Cuoco, et al.
European Urology Oncology|November 3, 2022
Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumChun Loo Gan, Jiaming Huang, Elizabeth Pan, et al.
Pageof 8